Comments
Dr Reddy’s Laboratories said today it has launched Eszopiclone tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTA (Eszopiclone) tablets C-IV, in the US market on Tuesday, following approval by the United States Food & Drug Administration (USFDA). The drug is helpful in the treatment of insomnia.
The Lunesta (Eszopiclone) tablets C-IV brand and generic combined had US sales of approximately $887 million for the most recent 12 months ending in January 2014, according to IMS Health*.
Dr Reddy’s Eszopiclone Tablets (C-IV) 1 mg is available in bottle counts of 30. Eszopiclone Tablets (C-IV) 2 mg and 3 mg are available in bottle counts of 100, according to a press release.
Glenmark ANDA
PTI adds: Glenmark Generics Inc, a subsidiary of Glenmark Generics Ltd, said in a separate statement that it has been granted final abbreviated new drug approval from the FDA for Eszopiclone tablets.
“Glenmark will commence distribution of the product immediately. The approval is for the 1 mg, 2 mg and 3 mg tablets,” Glenmark said in the statement.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.